{
  "nctId": "NCT03092934",
  "briefTitle": "A Study of AK-01 (LY3295668) in Solid Tumors",
  "officialTitle": "A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",
  "protocolDocument": {
    "nctId": "NCT03092934",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-04-10",
    "uploadDate": "2021-04-12T09:44",
    "size": 2319150,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03092934/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 13,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-05-29",
    "completionDate": "2020-04-20",
    "primaryCompletionDate": "2020-04-20",
    "firstSubmitDate": "2017-03-22",
    "firstPostDate": "2017-03-28"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Have received at least 1 but no more than 4 prior systemic therapies\n* Have adequate organ function\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Have estimated life expectancy greater than or equal to (≥)12 weeks\n* Have fully recovered from radiation therapy or surgery, and are recovering from any acute adverse effects of other cancer therapies\n* Have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mitomycin-C or nitrosoureas at least 6 weeks prior\n* Female participants with reproductive potential agree to use 2 forms of highly effective contraception during the study and for the following 3 months\n* Male participants must use a barrier method of contraception during the study and for the following 3 months\n\nPhase 1\n\n* Have evidence of a solid tumor that is locally advanced and/or metastatic (excluding primary brain tumor)\n\nPhase 2\n\n* Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1\n* Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:\n\n  * Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy\n  * Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor\n  * Triple negative breast cancer (TNBC) and failed standard therapy\n  * Squamous cell cancers of the head neck associated with the human papilloma virus (HPV), and have failed standard therapy\n  * Other solid tumor type that has been approved by the sponsor\n\nExclusion Criteria:\n\n* Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not current receiving corticosteroids) or a primary tumor of the CNS\n* Have a medical condition that precludes participation (swallowing disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Phase 1: Maximum Tolerated Dose",
        "description": "Maximum Tolerated Dose (MTD) was defined as the dose immediately below the dose at which ≥2/3, ≥2/6, or ≥3/9 participants in a cohort experienced a dose limiting toxicity (DLT) during the first 21 days of treatment (Cycle 1) in Phase 1.",
        "timeFrame": "Cycle 1 (21 days)"
      },
      {
        "measure": "Phase 2: Percentage of Participants Who Achieved Partial Response (PR) or Complete Response (CR) [Objective Response Rate (ORR)]",
        "description": "Objective response rate (ORR) was defined as a percentage of responders who achieved complete response or partial response (CR+PR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1). Complete response (CR) is defined as disappearance of all target (and non-target) lesions, and no appearance of new lesion. Partial response (PR) was defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions, taking as reference the baseline sum of LD, no progression of non-target lesions, and no appearance of new lesions.",
        "timeFrame": "Baseline to Objective Disease Progression (Up to 11 months)"
      }
    ],
    "secondary": [
      {
        "measure": "Phase 1: Number of Participants With One or More Treatment-Emergent Adverse Events",
        "description": "A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.",
        "timeFrame": "Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)"
      },
      {
        "measure": "Phase 2: Number of Participants With One or More Treatment-Emergent Adverse Events",
        "description": "A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.",
        "timeFrame": "Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)"
      },
      {
        "measure": "Phase 2: Pharmacokinetic (PK): Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC[0-12]) (Phase 2)",
        "description": "Area under the plasma concentration-time curve for LY3295668 from time zero to 12 hours.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 - 12 hours postdose; Cycle 1: Day 2 and Day 8 predose"
      },
      {
        "measure": "Phase 2: PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-dose (AUC[0-24])",
        "description": "Area under the plasma concentration-time curve for LY3295668 from time zero to 24 hours.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8-12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose"
      },
      {
        "measure": "Phase 2: PK: Maximum Observed Plasma Concentration (Cmax)",
        "description": "Maximum observed plasma concentration for LY3295668.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 hours post-dose"
      },
      {
        "measure": "Phase 2: PK: Time of Maximum Observed Plasma Concentration (Tmax)",
        "description": "Time of maximum observed plasma concentration of LY3295668.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 hours post-dose"
      },
      {
        "measure": "Phase 2: PK: Apparent Terminal Elimination Half-life (t1/2)",
        "description": "Apparent terminal elimination half-life of LY3295668.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8-12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose"
      },
      {
        "measure": "Phase 2: PK: Apparent Total Plasma Clearance (CL/F)",
        "description": "Apparent total plasma clearance of LY3295668.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 -12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose"
      },
      {
        "measure": "Phase 2: PK: Apparent Volume of Distribution (Vz/F)",
        "description": "Apparent volume of distribution of LY3295668.",
        "timeFrame": "Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 -12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose"
      },
      {
        "measure": "Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 White Blood Cell Count (WBC)",
        "description": "Presented are participants with the worst post-baseline WBC Grade \\>= 3 using the National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events version 4.03 (CTCAE v4.03). where Grade 1: \\< Lower Limit Normal (LLN) - 3000/mm3; \\<LLN - 3.0 x10e9/L, Grade 2: \\<3000 - 2000/mm3; \\<3.0 - 2.0 x10e9/L, Grade 3: \\<2000 - 1000/mm3; \\<2.0 1.0 x10e9/L, Grade 4: \\<1000/mm3; \\<1.0 x10e9/L.",
        "timeFrame": "Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)"
      },
      {
        "measure": "Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Neutrophils (Segmented and Blended)",
        "description": "Presented are participants with the worst post-baseline neutrophils Grade \\>=3 using the NCI-CTCAE v4.03 where Grade 1: \\< LLN - 1500/mm3; \\<LLN - 1.5 x10e9/L, Grade 2: \\<1500 - 1000/mm3; \\<1.5 - 1.0 x10e9/L, Grade 3: \\<1000 - 500/mm3; \\<1.0 - 0.5 x10e9/L, Grade 4: \\<500/mm3; \\<0.5 x 10e9/L.",
        "timeFrame": "Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)"
      },
      {
        "measure": "Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Lymphocytes",
        "description": "Presented are participants with the worst post-baseline lymphocytes Grade \\>=3 using the NCI-CTCAE version 4.03 where Grade 1: \\<LLN - \\<800/mm3, \\<LLN - 0.8 x 10e9/L, Grade 2: \\<800 - 500/mm3; \\<0.8 - 0.5 x 10e9/L, Grade 3: \\<500 - 200/mm3; \\<0.5 - 0.2 x 10e9/L, \\<200mm3; \\<0.2 x 10e9/L.",
        "timeFrame": "Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 12,
      "otherCount": 0,
      "totalCount": 14
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 94,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:05.178Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}